Regístrese
Buscar en
Revista Colombiana de Reumatología
Toda la web
Inicio Revista Colombiana de Reumatología Historia de la enfermedad de Devic
Información de la revista
Vol. 18. Núm. 4.
Páginas 271-284 (Diciembre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 18. Núm. 4.
Páginas 271-284 (Diciembre 2011)
DOI: 10.1016/S0121-8123(11)70043-3
Acceso a texto completo
Historia de la enfermedad de Devic
History of Devic's disease
Visitas
14659
Antonio Iglesias Rodríguez1,
Autor para correspondencia
, Diana Gil2, José Félix Restrepo3, Antonio Iglesias Gamarra3
1 Fellow de Neurología, Hospital San Ignacio de Loyola. Chicago. EUA
2 Reumatología. Unidad de Reumatología, Universidad Nacional de Colombia
3 Profesor titular de Medicina Interna y Reumatología, Facultad de Medicina, Universidad Nacional de Colombia
Este artículo ha recibido
14659
Visitas
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

En este escrito hacemos una completa revisión de la enfermedad de Devic, desde sus primeras descripciones por Eugene Devic, hasta el concepto actual, donde es considerada una neuromielitis óptica. Exponemos las diferentes formas de presentación de la neuromielitis óptica así como los hallazgos clínicos y de laboratorio que permiten diferenciar esta entidad de la esclerosis múltiple, tarea que muchas veces no es fácil de realizar por la semejanza en la presentación clínica. Sin embargo es importante su diferenciación porque el tratamiento y el pronóstico difieren entre estas dos enfermedades. No obstante, el descubrimiento de los anticuerpos IgG anti NMO, dirigidos contra los canales de agua de acuaporina 4 fueron fundamentales en tal diferenciación. Realizamos una mención especial sobre la enfermedad de Devic y el lupus y finalmente hacemos unas notas sobre el tratamiento disponible para esta patología.

Palabras clave:
enfermedad de Devic
lupus eritematoso sistémico
neuromielitis óptica
esclerosis múltiple
Summary

In this paper we do a complete review of Devic's disease, from its first descriptions by Eugene Devic, to the current concept, which is considered a neuromyelitis optica (NMO). We present the different forms of presentation of NMO as well as clinical and laboratory findings that distinguish this entity from multiple sclerosis, a task that frequently is not easy to perform because of the similarity in clinical presentation. Its differentiation is important because the treatment and prognosis differ between these two diseases. However the discovery of NMO IgG antibodies directed against aquaporin-4 water channels was a critical step in such differentiation. We made special mention of Devic's disease and lupus, and finally make some notes on the available treatment for this pathology.

Key words:
Devic’disease
systemic lupus erythematosus
neuromyelitis optica
multiple sclerosis
El Texto completo está disponible en PDF
Referencias
[1.]
T.C. Allbut.
On the ophthalmoscopic signs of spinal disease.
Lancet, 1 (1870), pp. 76-78
[2.]
Achard and Guinon: Arch De mèd Expér, 1 (1889), pp. 696
[3.]
D. Giorgi.
Eugene Devic and the origin of neuromyelitis óptica. Eugène Devic el origine della neuromielite ottica.
Riv Italiana di Neurobiología, (2006), pp. 3-4
[4.]
E. Devic.
Myelíte aiguë dorse-lombaire avec névrite optique, autopsie.
Congress Français Medicine (Premiere Session, Lyon), pp. 434-439
[5.]
E. Devic.
MyelÍte subaiguë compliquée de névrite optique.
Bull Med, 8 (1894), pp. 1033-1034
[6.]
Gault F. De la neuromyélite optique aiguë. Thèse no 891, Faculté de Médecine et de Pharmacie de Lyon.
[7.]
Holden: Arch.
Ophth, 43 (1914), pp. 231
[8.]
Balser: Brain, 59 (1936), pp. 353
[9.]
Brain: Quart.
J. Med, 23 (1929-1930), pp. 343
[10.]
C. Goulden.
Optic neuritis and mielitis. Optic neuritis and myelitis.
Ophthalmic Review, 34 (1914), pp. 193-209
[11.]
G.M. Beck.
A case of diffuse myelitis associated with optic neuritis.
Brain, 50 (1927), pp. 687-703
[12.]
F.C. Stansbury.
Neuromyelitis optica (Devic's disease). Presentation of five cases with pathological study and review of the literature.
Arch ophtalmol, 42 (1949), pp. 292-335
[13.]
R.N. Mandler, L.E. Davis, D.R. Jeffery, M.K. Kornfeld.
Devis's neuromyelitis optica: a clinicophatological study of 8 patients.
Ann Neurol, 34 (1993), pp. 162-168
[14.]
R.S. April, E. Vansonnenberg.
A case of neuromyelitis optica (Devic'syndrome) in systemic lupus erythematosus: clinicophatological report and review of the literature.
Neurology, 26 (1976), pp. 1066-1070
[15.]
E.L. Kinney, R.L. Beroff, N.S. Rao, M.F. Lay.
Devic's syndrome and systemic lupus Erythematosus. A case report and review of the literature.
And Arch Neurol, 36 (1979), pp. 643-644
[16.]
M.R. Tola, E. Granieri, L. Caniatti, E. Paolino, C. Monetti, L. Dovigo, et al.
Systemic lupus Erythematosus presenting with neurological disorders.
J Neurol, 239 (1992), pp. 61-64
[17.]
S. Motumara, T. Tabira, Y. Kuroiwa.
A clinical comparative study of multiple sclerosis and neuro- Behcet's syndrome, Journal of Neurology.
Neurosurgery and Psychiatry, 43 (1980), pp. 210-213
[18.]
M. Goldman, A. Herode, S. Borenstein, A. Zanen.
Optic neuritis, transverse myelitis and anti-DNA antibodies nine years after thymectomy for myasthenia gravis.
Arth Rheum, 27 (1984), pp. 701-703
[19.]
J.M. Kahlenberg.
Neuromyelitis Optica Spectrum Disorder as an Initial Presentation of Primary Sjögren's Syndrome.
Neurology, (2011), pp. 343-348
[20.]
J.M. Kahlenberg.
Neuromyelitis Optica Spectrum Disorder as an Initial Presentation of Primary Sjögren's Syndrome.
Neurology, (2011), pp. 343-348
[21.]
S.M. Al-Deeb, B.A. Yaqub, W.O. Koja.
Devic's neuromyelitis optica and varicella.
J Neurol, 240 (1993), pp. 450-451
[22.]
J.C. Ortiz de Zarate, L. Tamaroff, R.E.P. Sica, J.A. Rodriguez.
Neuromyelitis óptica versus subacute necrotic myelitis: part II. Anatomical study of two cases.
F Neurosurg Psychiatry, 31 (1968), pp. 641-645
[23.]
T. Fukazawa, T. Hamada, K. Tashiro, F. Moriwaka, T. Yanagihara.
Acute transverse myelitis in multiple sclerosis.
J Neurol Sci, 100 (1990), pp. 217-222
[24.]
A. Leonardi, L. Arata, M. Farinelli, L. Cocito, A. Schenone, M. Tabaton, et al.
Cerebrospinal fluid and neurophatological study in Devic's syndrome. Evidence of intrathecal immune activation.
J Neurol Sci, 82 (1987), pp. 281-290
[25.]
R.J. Swingler, D.A.S. Compston.
The distribution of multiple sclerosis in the United Kingdom.
J Neurosurg Psychiatry, 49 (1986), pp. 1115-1124
[26.]
D.A.S. Compston.
Risk factors for multiple sclerosis: race or place?.
J Neurosurg Psychiatry, 53 (1990), pp. 821-823
[27.]
D.H. Miller, W.I. McDonald, L.D. Blumhardt, G.H. du Boulay, A.M. Halliday, G. Johnson, et al.
Magnetic resonance imaging in isolated non-compressive spinal cord syndromes.
Ann Neurol, 22 (1987), pp. 714-723
[28.]
K. Tashiro, K. Ito, Y. Maruo, S. Homma, T. Yamada, N. Fujiki, et al.
MR imaging of spinal cord in Devic disease.
J Comput Assist Tomogr, 11 (1987), pp. 516-517
[29.]
D.W. Paty, J.J. Oger, L.F. Kastrukoff, S.A. Hashimoto, J.P. Hooge, A.A. Eisen, et al.
MRI in the diagnosis of multiple sclerosis: prospective comparison of clinical evaluation, EPs.
Oligoclonal banding and CT. Neurology, 38 (1988), pp. 180-185
[30.]
A.J. Thompson, A.G. Kermode, D.G. MacManus, B.E. Kendall, D.P. Kingsley, I.F. Moseley, et al.
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.
BMJ, 300 (1990), pp. 631-634
[31.]
F. Fazekas, H. Offenbacher, S. Strasser-Fuch.
MRI of neuromyelitis optica: evidence for a distinc entity.
J Neurol Neurosurg Psychiatry, 59 (1994), pp. 1140-1142
[32.]
J. de Seze, T. Stojkovic, G. Breteau, C. Lucas, U. Michon- Pasturel, J.Y. Gauvrit, et al.
Acute myelopathies. Clinical, laboratory and outcome profiles in 79 cases.
Brain, 124 (2001), pp. 1509-1521
[33.]
J. de Seze, C. Lebrun, T. Stojkovic, D. Ferriby, M. Chatel, P. Vermersch, et al.
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.
Mult Scler, 9 (2003), pp. 521-525
[34.]
R. Bergamaschi, A. Ghezzi.
Devic's neuromyelitis optica: clinical features and prognostic factors.
Neurol Sci, 25 (2004), pp. s364-s367
[35.]
C.F. Lucchinetti, R.N. Mandler, D. McGavern, W. Bruck, G. Gleich, R.M. Ransohoff, et al.
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.
Brain, 125 (2002), pp. 1450-1461
[36.]
B.G. Weinshenker, D.M. Wingerchuk, I. Nakashima, K. Fujihara, V.A. Lennon.
OSMS in NMO, but not MS: proven clinically and pathologically.
Lancet Neurol, 5 (2006), pp. 110-111
[37.]
J.I. O’Riordan, H.L. Gallagher, A.J. Thompson, R.S. Howard, D.P. Kingsley, E.J. Thompson, et al.
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.
J Neurol Neurosurg Psychiatry, 60 (1996), pp. 382-387
[38.]
V. Déral-Stéphant, C. Roux-Lelièvre, R. Vignal, E. Stéphant, A. Faivre, P. Alla.
Neuromyélite optique de Devic : discussion diagnostique après dix ans d’évolution d’une neuropathie optique bilatérale sévère.
J Fr Ophtalmol, 31 (2008), pp. 705-709
[39.]
J. Sellner, M. Boggild, M. Clanet, R.Q. Hintzen, Z. Illes, X. Montalban, R.A. Du Pasquier, C.H. Polman, P.S. Sorensen, B. Hemmer.
EFNS guidelines on diagnosis and management of neuromyelitis optica.
European J Neurol, 17 (2010), pp. 1019-1032
[40.]
H. Nakajima, T. Hosokawa, M. Sugino, F. Kimura, J. Sugasawa, T. Hanafusa, T. Takahashi.
Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis.
BMC Neurol, 10 (2010), pp. 45
[41.]
D.M. Wingerchuk, W.F. Hogancamp, P.C. O’Brien, B.G. Weinshenker.
The clinical course of neuromyelitis optica (Devic's Syndrome).
Neurology, 53 (1999), pp. 1107-1114
[42.]
D.M. Wingerchuk, V. Lennon, C.F. Lucchinetti, S.J. Pittock, B.G. Weinshenker.
The spectrum of neuromyelitis optica.
Neurology, 6 (2007), pp. 805-815
[43.]
D.M. Wingerchuck, B.G. Weinshenker.
Neuromyelitis optica: clinical predictors of a relapsing course and survival.
Neurology, 60 (2003), pp. 848-853
[44.]
G.M. Preston, T.P. Carroll, W.B. Guggino, P. Agre.
Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein.
Science, 256 (1992), pp. 385-387
[45.]
R. Marignier, P. Giraudon, S. Vukusic, C. Confavreux, J. Honnorat.
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.
The Adv Neurol Disord, 3 (2010), pp. 311-321
[46.]
S.R. Kalluri, V. Rothhammer, O. Staszewski, R. Srivastava, F. Petermann, M. Prinz, B. Hemmer, T. Korn.
Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica.
Plos One, 6 (2001), pp. 1-11
[47.]
A.S. Verkman.
Aquaporins: translating bench research to human disease.
Journal of Experimental Biology, 212 (2009), pp. 1707-1715
[48.]
M. Amiry-Moghaddam, O.P. Ottersen.
The molecular basis of water transport in the brain.
Nat Rev Neurosci, 4 (2003), pp. 991-1001
[49.]
M.C. Papadopoulos, A.S. Verkman, M.C. Papadopoulos, A.S. Verkman.
Aquaporin-4 and brain edema.
Ped Nephrol, 22 (2007), pp. 778-784
[50.]
K. Aoki, T. Uchihara, K. Tsuchiya, A. Nakamura, K. Ikeda, Y. Wakayama.
Enhanced expression of aquaporin 4 in human brain with infarction.
Acta Neuropathol, 106 (2003), pp. 121-124
[51.]
M.C. Papadopoulos, S. Saadoun, D.K. Binder, G.T. Manley, S. Krishna, A.S. Verkman.
Molecular mechanisms of brain tumor edema.
Neuroscience, 129 (2004), pp. 1011-1020
[52.]
V.A. Lennon, D.M. Wingerchuk, T.J. Kryzer, S.J. Pittock, C.F. Lucchinetti, K. Fujihara, et al.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Lancet, 364 (2004), pp. 2106-2112
[53.]
V.A. Lennon, T.J. Kryzer, S.J. Pittock, A.S. Verkman, S.R. Hinson.
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin 4 water channel.
J E sp Med, 202 (2005), pp. 437-477
[54.]
S.J. Pittock, V.A. Lennon, J. de Seze, P. Vermersch, H.A. Homburger, D.M. Wingerchuck, et al.
Neuromyelitis optica and non organ-specific autoimmunity.
Arch Neurol, 63 (2006), pp. 964-968
[55.]
S.J. Pittock, B.G. Weinshenker, C.F. Lucchinetti, D.M. Wingerchuck, J.R. Corboy, V.A. Lennon.
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.
Arch Neurol, 63 (2006), pp. 964-968
[56.]
S.F. Roemer, J.E. Parisi, V.A. Lennon, E.E. Benarroch, H. Lassmann, W. Bruck, et al.
Pattern specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Brain, 130 (2007), pp. 1194-1205
[57.]
M. Bradl, T. Misu, T. Takahashi, M. Watanabe, S. Mader, M. Reindl, et al.
Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo.
Ann Neurol, 66 (2009), pp. 630-643
[58.]
S. Saadoun, P. Waters, B.A. Bell, A. Vicent, A.S. Verkman, M.C. Papadopoulos.
Intracerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
Brain, 133 (2010), pp. 349-361
[59.]
J. Kira.
Neuromyelitis Optica and Asian Phenotype of Multiple Sclerosis.
Ann N Y Acad Sci, 1142 (2008), pp. 58-71
[60.]
M.J. Perwaiz, F. Hammoudeh, F. Schmidt.
Devic Syndrome: A Diagnostic Dilemma.
J Natl Med Assoc, 103 (2011), pp. 176-178
[61.]
T. Misu, K. Fujihara, A. Kakita, H. Konno, M. Nakamura, S. Watabane, et al.
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
Brain, 130 (2007), pp. 1224-1234
[62.]
T. Takahashi, K. Fujihara, I. Nakashima, T. Misu, I. Miyazawa, Nakamura, et al.
Anto-aguaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
Brain, 130 (2007), pp. 1235-1243
[63.]
P.H. Lalive, T. Mengue, I. Barman, B.A. Cree, C.P. Genain.
Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.
[64.]
D.M. Wingerchuck, V.A. Lennon, S.J. Pittock, C.F. Lucchinetti, B.G. Weinshenker.
Revised diagnostic criteria for neuromyelitis optica.
[65.]
Mayo clinic. Devic's Disease Symptoms. www.mayoclinic.org/devic-disease/symptoms.html. Accessed april 14, 2010.
[66.]
M. Matiello, A. Jacob, D.M. Wingerchuk, B.G. Weinshenker.
Neuromyelitis optica.
Curr Opin Neurol, 20 (2007), pp. 255-260
[67.]
A. Ghezzi, R. Bergamaschi, V. Martinelli, M. Trojano, M.R. Tola, E. Merelli, et al.
Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica.
J Neurol, 251 (2004), pp. 47-52
[68.]
W. Krampla, F. Aboul-Enein, J. Jecel, W. Lang, E. Fertl, W. Hruby, et al.
Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study.
Eur Radiol, 19 (2009), pp. 2535-2543
[69.]
M. Filippi, M.A. Rocca, L. Moiola, V. Martinelli, A. Ghezzi, R. Capra, et al.
MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica.
Neurology, 53 (1999), pp. 1705-1710
[70.]
I. Nakashima, K. Fujihara, I. Miyazawa, T. Misu, K. Narikawa, M. Nakamura, et al.
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG.
J Neurol Neurosurg Psychiatry, 77 (2006), pp. 1073-1075
[71.]
J. Sellner, N. Lüthi, W.M. Schüpbach, A. Gebhardt, O. Findling, G. Schroth, et al.
Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging and laboratory findings.
Spinal Cord, 47 (2009), pp. 312-317
[72.]
J. Cabrera-Gómez, A. Saiz-Hinarejos, F. Graus, A. González-Quevedo, R. Rodríguez-Rojas, L. Quevedo-Sotolongo, et al.
Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders.
Mult Scler, 14 (2008), pp. 248-251
[73.]
Y. Li, P. Xie, F. Lv, J. Mu, Q. Li, Q. Yang, et al.
Brain magnetic resonance imaging abnormalities in neuromyelitis optica.
Acta Neurol Scand, 118 (2008), pp. 218-225
[74.]
J. de Seze, T. Stojkovic, D. Ferriby, J.Y. Gauvrit, C. Montagne, et al.
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.
J Nuerol Sci, 197 (2002), pp. 57-61
[75.]
D.B. Bichuetti, R.L. Rivero, D.M. Oliveira, N.A. Souza, N. Abdala, E.M. Oliveira, et al.
Neuromyelitis optica: brain abnormalities in a Brazilian cohort.
Arq Neuropsiquiatr, 66 (2008), pp. 1-4
[76.]
E. Milano, A. Di Sapio, S. Malucchi, M. Capobianco, R. Bottero, A. Sala, et al.
Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse.
Neurol Sci, 24 (2003), pp. 130-133
[77.]
R. Bergamaschi, S. Tonietti, D. Franciotta, E. Candeloro, E. Tavazzi, G. Piccolo, et al.
Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.
Mult Scler, 10 (2004), pp. 2-4
[78.]
D. Lepur, V. Peterkovic, N. Kalabric.
Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis.
Neurol Sci, 30 (2009), pp. 51-54
[79.]
J. Kira.
Multiple sclerosis in the Japanese population.
Lancet Neurol, 2 (2003), pp. 117-127
[80.]
T. Takahashi, I. Miyazawa, T. Misu, R. Takano, I. Nakashima, K. Fujihara, et al.
Intractable hiccup and nausea in neuromyelitis optica with anti-aguaporin- 4 antibody: a herald of acute exacerbations.
J Neurol Neurosurg Psichiatry, 79 (2008), pp. 1075-1078
[81.]
M. Trojano, C. Avolio, C. Manzari, A. Calo, F. De Robertis, G. Serio, P. Livrea.
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.
F Neurosurg Psychiatry, 58 (1995), pp. 300-306
[82.]
S. Okinaka, T. Tsubaki, Y. Kuroiwa, Y. Toyokura, Y. Imamura.
Multiple sclerosis and allied disease in Japan; clinical characteristics.
Neurology, 8 (1958), pp. 756-763
[83.]
Y. Kuroiwa, A. Igata, K. Itahara, S. Koshijima, T. Tsubaki.
Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1084 cases.
Neurology, 25 (1975), pp. 845-851
[84.]
H. Shibasaki, W.I. McDonald, Y. Kuroiwa.
Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients.
J Neurol Sci, 49 (1981), pp. 253-271
[85.]
J. Kira.
Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders.
Ann Neurol, 40 (1996), pp. 569-574
[86.]
K. Yamasaki, I. Horiuchi, M. Minohara, Y. Kawano, Y. Ohyagi, T. Yamada, F. Mihara, H. Ito, Y. Nishimura, J. Kira.
HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunegenetic studies.
Brain, 122 (1999), pp. 1689-1696
[87.]
T.P. Hung.
Multiple sclerosis amongst Chinese in Taiwan.
J Neurol Sci, 27 (1976), pp. 459-484
[88.]
T. Tabira, et al.
Neuropathological features of MS in Japan.
Multiple Sclerosis East and West, pp. 273-295
[89.]
F. Ikuta.
Comparison of MS pathology between 70 American and 75 Japanese autopsy cases.
Mult Scler, (1982), pp. 297-306
[90.]
F. Barkhof, M. Filippi, D.H. Miller, P. Scheltens, A. Campi, C.H. Polman, et al.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Brain, 120 (1997), pp. 2059-2069
[91.]
S.J. Pittock, V.A. Lennon, K. Krecke, D.M. Wingerchuck, C.F. Lucchinetti, B.G. Weinshenker.
Brain abnormalities in neuromyelitis optica.
Arch Neurol, 63 (2006), pp. 390-396
[92.]
W. Kim, S. Kim, S.H. Lee, X.F. Li, H.J. Kim.
Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder.
MSJ, (2011), pp. 1-6
[93.]
A.A. Deodhar, T. Hochenedel, R.M. Bennett.
Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis.
J Rheumatol, 26 (1999), pp. 446-449
[94.]
J.F. Tellez-Zenteno, J.M. Remes-Troche, R.O. Negrete-Pulido, L. Dávila-Maldonado.
Longitudinal myelitis associated with systemic lupus Erythematosus: clinical features and magnetic resonance imaging of six cases.
Lupus, 10 (2001), pp. 851-856
[95.]
J. Birnbaum, D. Kerr.
Devic's syndrome in a woman with systemic lupus Erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody.
Arthritis Care Res, 57 (2007), pp. 347-351
[96.]
S. Paira, M. Benegas, A. Ortiz, C. Uña, O. Rillo, P. Mannucci, A. Allievi.
Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature.
Clin Rheumatol, 29 (2010), pp. 1335-1338
[97.]
A. McKeon, V.A. Lennon, T. Lotze, S. Tenenbaum, J.M. Ness, M. Rensel, et al.
CNS aquaporin-4 autoimmunity in children.
[98.]
M.A. Komolafe, E.O. Komolafe, T.A. Sunmonu, S.O. Olateju, C.M. Asaleye, O.A. Adesina, et al.
New onset neuromyelitis optica in young Nigerian woman with possible antiphospholipid syndrome: a case report.
J Med Case Reports, 2 (2008), pp. 348
[99.]
S. Ferreira, P. Marques, E. Carneiro, D. D’Cruz, G. Gama.
Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome.
Rheumatology (Oxford), 44 (2005), pp. 693-695
[100.]
A.Y. Chan, D.T. Liu.
Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome.
Rheumatology (Oxford), 45 (2006), pp. 120-121
[101.]
L.R. Mehta, M.K. Samuelson, A.K. Kleiner, A.D. Goodman, J.H. Anolik, R.J. Looney, et al.
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.
Mult Scler, 14 (2008), pp. 425-427
[102.]
F.G. Lehnhardt, P. Impekoven, A. Rubbert, L. Burghaus, M. Neveling, W.D. Heiss, et al.
Recurrent longitudinal myelitis as primary manifestation of SLE.
Neurology, 63 (2004), pp. 1976
[103.]
D. Karussis, R.R. Leker, A. Ashkenazi, O. Abramsky.
A subgroup of unusual clinical manifestations: do they represent a new nosological entity?.
Ann Neurol, 44 (1998), pp. 629-634
[104.]
L.K. Hummers, C. Krishnan, L. Casciola-Rosen, A. Rosen, S. Morris, J.A. Mahoney, et al.
Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies.
Neurology, 62 (2004), pp. 147-149
[105.]
A.C. Heinlein, E. Gertner.
Marked Inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus.
Lupus, 16 (2007), pp. 823-826
[106.]
J. Birnbaum, D. Kerr.
Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus.
Nat Clin Pract Rheumatol, 4 (2008), pp. 381-386
[107.]
J. Birnbaum, D. Kerr.
Devic's syndrome in a woman with systemic lupus erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody.
Arthritis Rheum, 57 (2007), pp. 347-351
[108.]
A. Mochizuki, A. Hyashi, S. Hisahara, S. Shoji, et al.
Steroid responsive Devic's variant in Sjögren's syndrome.
Neurology, 54 (2000), pp. 1391-1392
[109.]
A. Javed, R. Balabanov, B.W.G. Arnason, T.J. Kelly, N.J. Sweiss, P. Pytel, et al.
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis.
Mult Scler, 14 (2008), pp. 809-814
[110.]
K. Morgen, H.F. McFarland, S.R. Pillemer.
Central nervous system disease in primary Sjögren's syndrome: the role of magnetic resonance imaging.
Semin Arthritis Rheum, 34 (2004), pp. 623-630
[111.]
J. Kira, Y. Kawano.
Recurrent optic neuromyelitis with endocrinopathies.
Neurology, 49 (1997), pp. 1475-1476
[112.]
A.C. Hui, R.S. Wong, R. Ma, R. Kay.
Recurrent optic neuromyelitis with multiple endocrinopathies and autoimmune disorders.
J Neurol, 249 (2002), pp. 784-785
[113.]
D. Petraviæ, M. Habek, S. Supe, V.V. Brinar.
Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or a just coincidence?.
Mult Scler, 12 (2006), pp. 670-673
[114.]
M. Keegan, A.A. Pineda, R.L. McClelland, C.H. Darby, M. Rodriguez, B.G.l. Weinshenker.
Plasma Exchange for severe attacks of CNS demyelination: predictors of response.
Neurology, 58 (2002), pp. 143-146
[115.]
A. Theodoridou, L. Settas.
Demyelination in rheumatic diseases.
J Neurol Neurosurg Psychiatry, 77 (2006), pp. 290-329
[116.]
A.I. Kaplin, C. Krishnan, D.M. Deshpande, C.A. Pardo, D.A. Kerr.
Diagnosis and management of acute myelopathies.
[117.]
B.G. Weinshenker, P.C. O’Brien, T.M. Petterson, J.H. Noseworthy, C.F. Lucchinetti, D.W. Dodick, et al.
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
Ann Neurol, 46 (1999), pp. 878-886
[118.]
S. Llufriu, J. Castillo, Y. Blanco, L. Ramió-Torrentà, J. Río, M. Vallès, et al.
Plasma Exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months.
Neurology, 73 (2009), pp. 949-953
[119.]
S. Watanabe, I. Nakashima, T. Misu, I. Miyazawa, Y. Shiga, K. Fujihara, et al.
Therapeutic efficacy of plasma Exchange in NMO-IgG positive patients with neuromyelitis óptica.
Mult Scler, 13 (2007), pp. 128-132
[120.]
K. Ruprecht, E. Klinker, T. Dintelmann, P. Rieckmann, R. Gold.
Plasma exchange for severe optic neuritis: treatment of 10 patients.
Neurology, 63 (2004), pp. 1081-1083
[121.]
M. Bonnan, R. Valentino, S. Olindo, H. Mehdaoui, D. Smadja, P. Cabre.
Plasma Exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder.
Mult Scler, 15 (2009), pp. 487-492
[122.]
K. Miyamoto, S. Kusunoki.
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
Ther Apher Dial, 13 (2009), pp. 505-508
[123.]
D.M. Wingerchuk, V.A. Lennon, S.J. Pittock, C.F. Lucchinetti, B.G. Weinshenker.
Revised diagnostic criteria for neuromyelitis optica.
[124.]
R.N. Mandler, W. Ahmed, J.E. Dencoff.
Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.
Neurology, 51 (1998), pp. 1219-1220
[125.]
L. La Mantia, N. Mascoli, C. Milanese.
Azathioprine. Safety profile in multiple sclerosis patients.
Neurol Sci, 28 (2007), pp. 299-303
[126.]
J.M. Killian, R.B. Bressler, R.M. Armstrong, T.X. Houston.
Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis.
Arch Neurol, 45 (1988), pp. 27-30
[127.]
B. Weinstock-Guttman, M. Ramanathan, N. Lincoff, S.Q. Napoli, J. Sharma, J. Feichter.
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic Disease).
Arch Neurol, 63 (2006), pp. 957-963
[128.]
A. Jacob, B.G. Weinshenker, I. Violich, N. McLinskey, L. Krupp, R.J. Fox, et al.
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
Arch Neurol, 65 (2008), pp. 1443-1448
[129.]
E. Kimby.
Tolerability and safety of rituximab (Mab- Thera).
Cancer Treat Rev, 31 (2005), pp. 456-473
[130.]
F.G. Joseph, N.J. Scolding.
Neurolupus.
Pract Neurol, 10 (2010), pp. 4-15
Copyright © 2011. Asociación Colombiana de Reumatología
Opciones de artículo
Herramientas
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.